Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) Return on Capital Employed (2025)

Historic Return on Capital Employed for Neuphoria Therapeutics (NEUP) over the last 1 years, with Q4 2025 value amounting to 0.12%.

  • Neuphoria Therapeutics' Return on Capital Employed changed N/A to 0.12% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.12%, marking a year-over-year change of. This contributed to the annual value of 0.61% for FY2023, which is N/A changed from last year.
  • Per Neuphoria Therapeutics' latest filing, its Return on Capital Employed stood at 0.12% for Q4 2025.
  • Over the past 5 years, Neuphoria Therapeutics' Return on Capital Employed peaked at 0.04% during Q2 2025, and registered a low of 0.14% during Q3 2025.